Redx Pharma’s RXC008 gets FDA fast track for Crohn’s disease
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
ALDERLEY PARK, UK - Redx Pharma Ltd announced today that the U.S. Food and Drug Administration granted Fast Track Designation to RXC008 for the treatment of fibrostenotic Crohn’s disease, according to a press release statement.
Read full article at source